Survival Following Bilateral Staple Lung Volume Reduction Surgery for Emphysema*

Matthew Brenner, MD, FCCP; Robert J. McKenna, Jr., MD; John C. Chen, MD, FCCP; Kathy Osann, PhD; Ledford Powell, MD; Arthur F. Gelb, MD, FCCP; Richard J. Fischel, MD, PhD; and Archie F. Wilson, MD, PhD

Study objectives: Despite numerous reports of short-term response to lung volume reduction surgery (LVRS) for treatment of emphysema, to our knowledge, longer-term survival has not been reported. We describe survival following LVRS in a large cohort of 256 patients treated with bilateral staple LVRS (n = 236 video-assisted thoracic surgery [VATS] approaches, n = 20 median sternotomy) by a single group of physicians over a 3½-year period from April 1994 to November 1997.

Design: Prospective survival study. Overall survival, survival stratified by preoperative presentation, and acute postoperative response were investigated using Kaplan-Meier methods. The simultaneous effects of preoperative predictors and postoperative response variables on survival were examined using a Cox proportional hazards model.

Setting: Community hospital and university medical center.

Patients: We studied 256 consecutive patients with severe emphysema treated with LVRS.

Interventions: Bilateral staple LVRS by VATS.

Measurements and results: Overall survival information was known with certainty for 246 of 256 patients as of February 1, 1998. Median follow-up time was 623 days (range, 0 to 1,545 days). Mean FEV₁ was 0.635L ± 0.015 L preoperatively and rose to 1.068L ± 0.029 L postoperatively. By standard analysis methods (missing patients censored at the time of last contact), 1-year survival was 85 ± 2.3% compared with 83 ± 2.4% 1-year survival with “worst case” analytic methods (assuming all missing patients died). Two-year survival averaged 81 ± 2.7% by standard analysis vs 76 ± 2.9% by worst case evaluation. Survival was significantly better for patients who were younger (< 70 years old, p = 0.02) and with higher baseline FEV₁ (> 0.5, p < 0.03) and Po₂ (> 54, p < 0.001). Patients who had greatest short-term improvement in FEV₁ following surgery (> 0.56 L increase) also had significantly better longer-term survival following LVRS.

Conclusions: To our knowledge, this is the first longer-term survival analysis of a large series of patients who underwent bilateral staple LVRS for emphysema. Substantial long-term mortality is seen, particularly within identifiable high-risk subgroups. Careful comparison to comparably matched control patients will be needed to definitively assess the benefits and risks of LVRS. This study suggests that prospective, controlled trials may need to stratify patient randomization based on preoperative risk factors to obtain meaningful results.

(CHEST 1999; 115:390–396)

Key words: duration; emphysema; long term; LVRS; predictors; survival

Abbreviations: DLCO = carbon monoxide diffusing capacity; LVRS = lung volume reduction surgery; NIH = National Institutes of Health; VATS = video-assisted thoracoscopic surgery

Numerous studies have investigated short-term responses to lung volume reduction surgery (LVRS) for palliative treatment of emphysema.1–13

For editorial comment see page 318

However, the overall value of LVRS cannot be determined accurately until long-term follow-up results are known. Some recent studies investigate longer-term functional results, but to our knowledge,
long-term survival predictors following LVRS have not been reported.\textsuperscript{2,6,9,14–16}

The National Institutes of Health (NIH) is beginning a multicenter, randomized, prospective trial of LVRS in patients with advanced emphysema.\textsuperscript{17} In future years, the NIH trial may add valuable information regarding long-term and short-term outcomes of LVRS compared with medical management. However, there is currently limited information regarding longer-term (\(>1\) year) postoperative survival and survival predictors for patients undergoing LVRS.

In this study, we investigate survival following LVRS in a large cohort of patients treated with bilateral staple LVRS performed by a single group of physicians over a 3 1/2-year period from April 1994 to October 1997. Overall survival, as well as survival analysis based on preoperative presentation and acute postoperative response were assessed in all patients. Current survival information was available on all but 12 (5\%) of 256 patients who underwent bilateral staple LVRS during this period. Since the number of patients unavailable for follow-up was small but potentially significant, analysis was performed in two ways: (1) standard method, in which all 12 missing patients were censored at the time of last contact, and (2) a “worst case scenario,” in which all 12 patients were assumed to have died after the last contact. In this way, survival is analyzed under both limits of outcome possibilities.

Since patients with severely decreased FEV\(_1\), such as those enrolled in this study, have variable but significantly elevated mortality risks\textsuperscript{18,19} with standard medical management, we suspected there would be considerable long-term mortality following LVRS as well. We hypothesized that patients who had less severe underlying disease, greater preoperative oxygenation, and greatest short-term improvement in pulmonary function test results would have better long-term survival.

To our knowledge, this survival analysis represents the largest cohort to date of emphysema patients treated by a uniform bilateral staple reduction procedure and followed up for a prolonged period of time. This information should be helpful in assessing mortality risks following LVRS, prospective randomized controlled trial stratification, and may aid in patient selection for long-term LVRS benefit.

\section*{Materials and Methods}

Methods for patient selection, preoperative analysis, surgical procedures, and follow-up studies for patients undergoing bilateral LVRS in this clinical program have been described previously.\textsuperscript{3,20}

All patients who underwent bilateral staple LVRS at Chapman Medical Center from April 1994 to November 1997 were included in this evaluation. Patients underwent baseline complete pulmonary function testing, including spirometry, gas exchange measures (room air arterial blood gas measurement, carbon monoxide diffusion capacity [DLCO]), plethysmography, and gas dilution lung volumes. Maximum inspiratory and expiratory flow volume curves, and thoracic gas volume were measured in a plethysmograph (Collins/Cybermedic Classic TCI and Body Plethysmograph; Warren E. Collins Inc; Braintree, MA), and compared with predicted values as previously described.\textsuperscript{3,20} All patients underwent LVRS at Chapman Medical Center by one or both of the two thoracic surgeons in the research group (R.J.M., R.J.F.); no procedures were performed at any other center in this protocol.

Repeated pulmonary function studies were requested from patients 3 months postoperatively, at 6 months, and at approximately 6-month intervals thereafter. Whenever possible, repeated spirometry was performed at least once at Chapman Medical Center within 3 months of surgery, but subsequent spirometry data were obtained from the referring site.

Informed consent for surgery and preoperative evaluation was obtained from all patients. Despite maximal medical management, all patients were markedly symptomatic. Chest radiographs showed hyperexpansion of the thorax with flattening or inversion of the diaphragm.

Contraindications to surgery included current cigarette smoking, age > 80 years, severe cardiac disease (congestive heart failure, significant coronary or valvular disease), history of cancer within the last 5 years, ventilator dependency, or prior thoracic surgery. Relative contraindications included age > 75 years, severe anxiety, severe depression, or CO\(_2\) retention with resting \(\text{Paco}_2\) > 55 mm Hg.\textsuperscript{3,20}

To be accepted for the procedure, the pattern of emphysema on CT had to be severe and heterogeneous. Radionuclide lung perfusion scans were also used to confirm the heterogeneous pattern of emphysema.\textsuperscript{3,20}

\section*{Thoracoscopic LVRS Operative Methods}

Operative procedures for bilateral thoracoscopic staple volume reduction surgery have been described previously as well.\textsuperscript{3,20} Patients underwent video-assisted thoracic surgery (VATS) under paralyzed general anesthesia (isoflurane) using a left-sided double-lumen tube (Mallincrodt Anesthesia; St. Louis, MO).

Procedures were performed by one surgical group (RM, RF, MM) with patients in the lateral decubitus position. The trocar and thoracoscope were placed through the 10th intercostal space in the posterior axillary line. Three additional 1- to 2-cm incisions were made for standard instruments. Patients were turned to the contralateral decubitus position for separate sterile preparation and draping after completion of surgery on the initial side.

Preoperative lung CT scans and ventilation/perfusion scans were used to identify areas of dysfunctional or degenerated lung targeted for resection with the staples.\textsuperscript{3,20} Ring forceps manipulated the lung into a 60-mm endoscopic stapler (ELC 60; Ethicon; Cincinnati, OH) with bovine pericardium (Peristrips; Biovascular; Saint Paul, MN) or Instat (Johnson and Johnson; New Brunswick, NJ) to buttress the staples. The staples were fired an average of 15 times for bilateral operations. Typically, approximately half of the upper lobe was resected in patients with upper lobe disease.

\section*{Survival}

Survival status was assessed for all patients by contacting them directly or their referring physicians between January and Feb-
mary, 1998. The latest date of known survival was recorded, and the date and cause of death (if known) were recorded for patients who died. Information on cause of death when available was obtained from families or referring physicians.

A total of 12 patients were unavailable for follow-up as of January 1998. For these patients, the last known date of contact was recorded and used as the censoring date in the first analysis method, and used as the potential date of death in the “worst case” scenario analyses.

Acute Response Evaluation

The change in FEV₁, FVC, and dyspnea score at the time of initial follow-up was determined for all patients whose initial follow-up visits were within 1 year of surgery. The short-term postoperative improvement was defined as the FEV₁ measured closest to 6 months following surgery.

Rehabilitation

Patients did not receive preoperative rehabilitation at Chapman Medical Center prior to LVRS. All patients underwent a similar regimen of pulmonary rehabilitation at the Medical Center, beginning immediately following hospital discharge. The rehabilitation consists of a 10-day outpatient regimen involving a multidisciplinary approach with nursing, respiratory, dietary, nutritional, psychosocial, occupational, and physical therapy. Patient education, physical exercise (walking, flexibility, and strengthening), self-monitoring, breathing retraining, and bronchial hygiene instruction are included.

Statistical Analysis

Baseline characteristics and group descriptive characteristics are reported as mean and standard errors. The overall survivor function is estimated using the Kaplan-Meier method. Differences in survival after stratification by preoperative and postoperative variables were tested using the log-rank test (Tarone-Ware test). The simultaneous importance of preoperative and postoperative variables on survival were investigated using Cox proportional hazards regression. Covariate analysis was performed, including variables found to be significant in univariate survival. Survival analyses were performed using Kaplan-Meier methods and with Cox proportional hazards analysis. Analyses were conducted using a statistical software package (Systat 7.0 for Windows; SPSS Inc; Chicago, IL).

RESULTS

Composite Results in All Patients

A total of 256 patients (165 male, 91 female) underwent bilateral staple LVRS in this program during the analysis interval. Average age was 67 ± 0.4 years. There were 13 perioperative deaths (defined as deaths within 30 days of surgery); 30-day mortality rate was 5 ± 1.5% in this group.

Baseline characteristics are summarized in Table 1. Mean FEV₁ was 0.635L ± 0.015 L preoperatively and rose to 1.068L ± 0.042 L postoperatively (at an average of 5 ± 2.5 months). Short-term improvement in FEV₁ following surgery was 0.43L ± 0.02 L (41 ± 5% change from baseline). Baseline dyspnea score for all patients in this study was 3.1 ± 0.05. Dyspnea score improved acutely following surgery by 1.8 ± 0.08 to 1.37 ± 0.08 in survivors.

Overall Survival

Overall survival information was known with certainty for 246 of 256 patients as of February 1, 1998. Median follow-up time was 623 days (± 23.6 days; range, 0 to 1,545 days) until cutoff date (n = 193), censoring when unavailable for follow-up (n = 12), or death (n = 51). The 12 patients unavailable for follow-up were followed up a mean of 391 days at the times of last contact.

Overall survival by standard and worst-case scenario analyses is shown in Figure 1. By standard analysis, 1-year survival is 85 ± 2.3% compared with 83 ± 2.4% 1-year survival with worst case analytic methods. Two-year survival averaged 81 ± 2.7% by standard analysis vs 76 ± 2.9% by worst-case evaluation. Three-year survival information is available on 24 patients. Patient survival at 3 years is 72 ± 4.4% by standard and 67 ± 4.4% by worst case analysis methods. No differences were seen in survival between men and women (Fig 2, A).

Effect of Operative Procedure

Bilateral thorascopic staple LVRS by VATS was performed in the vast majority of patients (n = 236). However, early in the program, 20 patients underwent LVRS via median sternotomy. Survival following median sternotomy in this series of patients was significantly worse than in patients who underwent bilateral thorascopic LVRS (p < 0.001) (Fig 2, B). One-year survival was 55 ± 11% for median sternot-

| Table 1—Comparison of Baseline Values for VATS- vs Median Sternotomy-Treated Patients* |
|-------------------------------------|-----|-----|-----|-----|-----|
|                                    | VATS | Mean | SD  | Median Sternotomy | Mean | SD  |
| Age, yr                            | 67   | 6.87 | 66  | 11.04 | 0.80 |
| DLCO, mL/min/mm Hg                 | 5.2  | 2.67 | 5.3 | 2.57   | 0.89 |
| FEV₁, % predicted                  | 24.4 | 8.35 | 25.0| 5.84   | 0.80 |
| FEV₁, L                            | 0.6  | 0.23 | 0.7 | 0.23   | 0.23 |
| FVC, % predicted                   | 49.6 | 14.81| 52.9| 19.12  | 0.65 |
| FVC, L                             | 1.9  | 0.69 | 2.3 | 0.96   | 0.31 |
| Pco₂, mm Hg                        | 42.5 | 7.21 | 41.1| 4.67   | 0.44 |
| Po₂, mm Hg                         | 65.1 | 11.94| 63.8| 7.69   | 0.65 |
| RV, % predicted                    | 201.1| 57.47| 192.0|39.42  | 0.54 |
| RV, L                              | 4.5  | 1.48 | 4.8 | 0.62   | 0.26 |
| RV/TLC                             | 0.7  | 0.10 | 0.6 | 0.11   | 0.75 |
| TLC, % predicted                   | 125.1| 22.57| 115.9|8.21   | 0.02 |
| TLC, L                             | 7.2  | 1.71 | 7.5 | 0.65   | 0.23 |

*RV = residual volume; TLC = total lung capacity.
omy patients vs 88 ± 2% for thorascopic LVRS by VATS patients (standard analysis methods). Two-year survival was 40 ± 12% for median sternotomy vs 83 ± 2.7% for VATS-treated patients. Most of the mortality in the median sternotomy patients was acute, with 30-day mortality of 25 ± 11%. In contrast, acute 30-day mortality rates were 3.0 ± 1% for thoracoscopic LVRS. For this reason, bilateral thoracoscopic LVRS by VATS is used almost exclusively in this program currently.

At preoperative baseline, there were no significant differences between patients who underwent VATS vs median sternotomy, except a slightly lower total lung capacity (115% predicted vs 124%) for median sternotomy patients vs VATS, respectively (p = 0.03).

**FEV<sub>1</sub>**

Patients with higher baseline FEV<sub>1</sub> (>0.50 L, n = 172) had improved survival compared to patients with lower baseline FEV<sub>1</sub> (≤0.50 L, n = 79) (p = 0.03) as seen in Figure 2, C. Similar findings were seen if baseline FEV<sub>1</sub> percent predicted (cutoff value 19% predicted) was used rather than absolute FEV<sub>1</sub> values (p = 0.04). For patients who underwent LVRS by VATS methods, 1-year survival was 81 ± 4.7% for those with FEV<sub>1</sub> < 0.5 L vs 90 ± 2% for those with higher baseline FEV<sub>1</sub>.

Surviving patients whose FEV<sub>1</sub> improved most at initial follow-up (increase in FEV<sub>1</sub> > 0.56 L, n = 56) appeared to have significantly lower long-term mortality (p < 0.04) than the 154 patients with short-term follow-up visits revealing an increase in FEV<sub>1</sub> of ≤ 0.56 L over baseline. Findings were similar when evaluated as increases in percent predicted FEV<sub>1</sub>; patients whose conditions improved >16% of predicted (n = 89) from baseline had significantly greater long-term survival than patients whose conditions did not improve as much (n = 113) at early follow-up (p = 0.04) (Fig 2, D and E).

**Age**

As expected, younger patients ≤ 70 years old (n = 176) had improved long-term survival (1 year, 88 ± 2.5%; 2 year, 85 ± 3%) compared with older patients >70 years old (n = 76, 1-year survival, 80 ± 4.6%; 2-year survival, 72 ± 5%) (p = 0.02, Fig 2, F).

**Gas Exchange**

Baseline hypoxemia (Pa<sub>O<sub>2</sub> ≤ 55, n = 47) also predicted poorer long-term survival (p = 0.001) (Fig 2, G). For VATS-treated patients, Pa<sub>O<sub>2</sub> ≤ 55 mm Hg was 75 ± 6.6% at 1 year vs 90 ± 2.3% survival in patients with preoperative Pa<sub>O<sub>2</sub> > 55. Baseline PaCO<sub>2</sub> showed trends toward worsening survival with elevated PaCO<sub>2</sub>, but did not reach statistical significance (Fig 2, H). Preoperative DLCO levels were not significantly associated with long-term survival at any cut point.
Multivariate Survival Analysis

Multivariate analysis using the preoperative variables found to be significant in univariate testing (\(\text{PaO}_2\), age, \(\text{FEV}_1\) percent predicted, procedure approach) revealed all variables to be significant independent predictors of outcome (all \(p < 0.01\)) except for \(\text{FEV}_1\) percent predicted (\(p = 0.14\)).

Discussion

Numerous recent studies report early pulmonary function and symptomatic improvement in selected patients following bilateral staple LVRS procedures for relief of emphysema symptoms.\(^2,3,5–7,10,11,21–26\) Operative mortality rates have generally been reported between 0 and 8%.\(^3,5,6,10,11,13,15,24–27\) However, to our knowledge, longer-term survival studies and factors associated with long-term mortality have not been published.

Long-term survival information for patients undergoing LVRS is important for providing prognostic information, selecting patients for surgery, assessing the long-term value of the procedures, and defining success following surgery. We hypothesized that certain subgroups of patients undergoing LVRS would have long-term survival advantages. Preoperatively, we predicted that patients with lesser degrees of overall emphysema, younger age, and higher levels of oxygenation would be better able to survive for longer periods of time postoperatively. Additionally, we thought that patients who experienced greatest short-term improvement following surgery would also have improved long-term survival.

Most of the survival analysis results of this study are not surprising, though the magnitude of survival impact differences based on preoperative variables was impressive for a number of variables. As expected, low preoperative FEV\(_1\), hypoxemia, and advanced age were clearly associated with reduced long-term survival. Surviving patients who experienced the greatest incremental improvements in FEV\(_1\) shortly following surgery also had improved long-term survival.

Mortality with median sternotomy was higher than bilateral LVRS by VATS in this series, with most deaths occurring within 30 days of surgery. There were far fewer median sternotomy procedures (20) than thoracoscopic procedures (236). The median sternotomy procedures were performed early in the bilateral LVRS program and may represent a learning curve phenomenon. However, the surgeons were already very experienced with unilateral LVRS by...
improvements. FEV\textsubscript{1} has been shown to correlate with short-term improvement and long-term survival. Postoperative improvement can be defined by a number of objective and subjective variables. Improvement in flows, volumes, gas exchange, or dyspnea can all be considered outcome variables. In this study, we focused on FEV\textsubscript{1} and dyspnea scale score improvements. FEV\textsubscript{1} has been shown to correlate with long-term survival in patients with emphysema. Dyspnea scores are subjective but are clinically relevant to patients. Improvement in outcome variables can be measured as absolute changes following surgery from baseline, or as the percent improvement compared with baseline values. We chose to examine absolute improvement measures rather than percent changes from baseline, because percent change measurements are greatest in patients with the lowest baseline values and “exaggerate” changes in the most compromised patients who would not be expected to survive longest.

There are a number of limitations to this study. When we analyzed preoperative variables to predict long-term survival outcome, “cut points” must be interpreted with caution. Clearly, they do not represent fixed “cutoff” values for acceptable or unacceptable outcomes. Statistically, they represent points on a continuum of statistical probability where greater likelihood of improved outcome exists on one side compared with another side of the cut. Individual judgment must be retained in making decisions regarding outcome and treatment of patients.

While it is useful to examine the variables that influence survival outcomes following LVRS in this study, it is not possible to compare survival in these patients who underwent LVRS procedures to patients who have been medically managed. A comparable control group can realistically be obtained only by a controlled trial such as the upcoming NIH study. However, since marked differences in survival are seen based on preoperative parameters in the current investigation, it may be necessary to stratify patients during prospective randomization based on preoperative risk group categories or spurious results may occur in prospective trials.

Most importantly, one cannot conclude that sub-
groups of patients who are identified as having poor long-term survival following LVRS are poor candidates for LVRS therapy, since they may be the same patients who would also have poor long-term survival chances with medical management. Only comparison with a comparably matched control group can answer these important questions.

There are additional limitations of this study. Patients involved in this study met very specific, narrowly defined selection criteria. Any findings from this study do not apply to and cannot be extrapolated to patients who do not meet the entry criteria of this study. In particular, the large proportion of patients with relatively homogeneously distributed emphysema were excluded from LVRS in this study, and their response to LVRS cannot be inferred.

We examined expiratory flow as the primary outcome measure to define short-term LVRS operative success for correlations with long-term survival. There is evidence that lung volume, gas exchange, and exercise measurements may be of equal or greater clinical importance.

The follow-up survival information is relatively complete from this very large group of patients in this study. However, the 12 patients who were unavailable for follow-up do affect overall mortality statistics as can be seen by the “best” and “worst case scenarios” analyzed and this study.

To our knowledge, this study represents the first report of a large cohort of patients studied for longer-term survival following bilateral staple LVRS. The group of patients is unique in that all patients were treated by one group of physicians, at a single center, with relatively complete longer-term survival follow-up information. Substantial long-term mortality is seen, particularly within identifiable high-risk subgroups. Careful comparison to comparably matched control patients, stratified by risk category, with longer-term follow-up will be needed to definitively assess the benefits and risks of LVRS.

REFERENCES

1 Cooper JD, Trulock EP, Triantafillou AN, et al. Bilateral pneumectomy (volume reduction) for chronic obstructive pulmonary disease. J Thorac Cardiovasc Surg 1995; 109:106–116; discussion 116–119
2 Cooper JD, Patterson GA, Sundaresan RS, et al. Results of 150 consecutive bilateral lung volume reduction procedures in patients with severe emphysema [see comments]. J Thorac Cardiovasc Surg 1996; 112:1319–1329; discussion 1329–1330
3 McKenna RJ Jr, Brenner M, Fischel RJ, et al. Should lung volume reduction for emphysema be unilateral or bilateral? J Thorac Cardiovasc Surg 1996; 112:1331–1338; discussion 1338–1339
4 McKenna RJ Jr, Brenner M, Gelb AF, et al. A randomized, prospective trial of stapled lung reduction versus laser bul-
lectomy for diffuse emphysema [see comments]. J Thorac Cardiovasc Surg 1996; 111:317–321; discussion 322
5 Sciurba FC, Rogers RM, Keenan BJ, et al. Improvement in pulmonary function and elastic recoil after lung-reduction surgery for diffuse emphysema [see comments]. N Engl J Med 1996; 334:1095–1099
6 Stammberger U, Thurnheer R, Bloch KE, et al. Thoracoscopic bilateral lung volume reduction for diffuse pulmonary emphysema. Eur J Cardiothorac Surg 1997; 11:1005–1010
7 Argenziano M, Thomashow B, Jellen PA, et al. Functional comparison of unilateral versus bilateral lung volume reduction surgery. Ann Thorac Surg 1997; 64:321–326; discussion 326–327
8 Bagley PH, Davis SM, O'Shea M, et al. Lung volume reduction surgery at a community hospital: program development and outcomes. Chest 1997; 111:1552–1559
9 Cordova F, O'Brien G, Furukawa S, et al. Stability of improvements in exercise performance and quality of life following bilateral lung volume reduction surgery in severe COPD. Chest 1997; 112:907–915
10 Hazeltine SR, Boley TM, Nunnhein KS, et al. Effect of bovine pericardial strips on air leak after stapled pulmonary resection. Ann Thorac Surg 1997; 63:1573–1575
11 Kotloff RM, Tino G, Bavaria JE, et al. Bilateral lung volume reduction surgery for advanced emphysema: a comparison of median sternotomy and thoracoscopic approaches. Chest 1996; 110:1399–1406
12 Miller JI Jr, Lee RB, Mansour KA. Lung volume reduction surgery: lessons learned [see comments]. Ann Thorac Surg 1996; 61:1464–1468; discussion 1468–1469
13 Szekely LA, Oelberg DA, Wright C, et al. Preoperative predictors of operative morbidity and mortality in COPD patients undergoing bilateral lung volume reduction surgery. Chest 1997; 111:550–558
14 Yusen RD, Trulock EP, Pohl MS, et al. Results of lung volume reduction surgery in patients with emphysema: the Washington University Emphysema Surgery Group. Semin Thorac Cardiovasc Surg 1996; 8:99–109
15 Gelb AF, Brenner M, McKenna RJ Jr, et al. Lung function 12 months following emphysema resection. Chest 1996; 110:1407–1415
16 Sciurba FC. Early and long-term functional outcomes following lung volume reduction surgery. Clin Chest Med 1997; 18:239–276
17 Benditt JO, Albert RK. Surgical options for patients with advanced emphysema. Clin Chest Med 1997; 18:577–593
18 Traver GA, Cline MG, Burrows B. Predictors of mortality in chronic obstructive pulmonary disease: a 15-year follow-up study. Am Rev Respir Dis 1979; 119:895–902
19 Burrows B, Bloom JW, Traver GA, et al. The course and prognosis of different forms of chronic airways obstruction in a sample from the general population. N Engl J Med 1987; 317:1309–1314
20 Gelb AF, Zamel N, McKenna B Jr, et al. Mechanism of short-term improvement in lung function after emphysema resection. Am J Respir Crit Care Med 1996; 154(pt 1):945–951
21 Brenner M, McKenna B Jr, Gelb A, et al. Objective predictors of response for staple versus laser emphysematous lung resection. Am J Respir Crit Care Med 1997; 155:1295–1301
22 Cooper JD, Patterson GA. Lung-volume reduction surgery for severe emphysema. Chest Surg Clin North Am 1995; 5:815–831
23 Daniel TM, Chan BB, Bhaskar V, et al. Lung volume reduction surgery: case selection, operative technique, and clinical results. Ann Surg 1996; 223:326–331; discussion 332–333
24 Keller CA, Ruppel G, Hibbett A, et al. Thoracoscopic lung volume reduction surgery reduces dyspnea and improves exercise capacity in patients with emphysema. Am J Respir Crit Care Med 1997; 156:60–67
25 Martinez FJ, de Oca MM, Whyte RI, et al. Lung-volume reduction improves dyspnea, dynamic hyperinflation, and respiratory muscle function. Am J Respir Crit Care Med 1997; 155:1984–1990
26 Argenziano M, Mozzani N, Thomashow B, et al. Extended indications for lung volume reduction surgery in advanced emphysema. Ann Thorac Surg 1996; 62:1588–1597
27 Fujita RA, Barnes GB. Morbidity and mortality after thoracoscopic pneumonoplasty. Ann Thorac Surg 1996; 62:251–257
28 Weder W, Schmied RA, Russi EW. Thoracoscopic lung volume resection surgery for emphysema. Int Surg 1996; 81:229–234
29 Stamatis G, Teschler H, Fechner S, et al. Bilateral lung volume reduction in patients with severe pulmonary emphysema [see comments]. Pneumologie 1996; 50:448–452